Author: Ravi Shankar

• Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold

• KRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%, highlighting its potential to reduce toxic protein accumulation in the liver

• Best-in-class preclinical profile supports KRRO-111’s potential to address both liver and lung manifestations of AATD; regulatory submission expected in the first half of 2027

CAMBRIDGE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced preclinical results for its pipeline program KRRO-111 for the potential treatment of alpha-1 antitrypsin deficiency (AATD) delivered subcutaneously. The results highlight KRRO-111’s potential best-in-class profile and its ability to address both the lung and liver manifestations of AATD through a differentiated RNA editing approach.

“In these preclinical studies, KRRO-111 restored functional M-AAT while reducing the toxic Z-AAT that drives liver injury,” said Loïc Vincent, PhD, Chief Scientific Officer of Korro. “That dual profile, with a redosable subcutaneous drug presentation, is what we believe a next-generation AATD therapy needs to support all AATD patients.”

KRRO-111 is a proprietary GalNAc-conjugated RNA-editing oligonucleotide administered subcutaneously and selectively taken up by liver cells. Once inside the liver cells KRRO-111 harnesses endogenous Adenosine Deaminase Acting on RNA (ADAR) enzymes to correct the pathogenic SERPINA1 transcript, enabling production of M-AAT, while reducing synthesis of mutant Z-AAT.

KRRO-111 exhibited potent RNA editing activity (EC50 ~1 nM) achieving up to 98% editing in mouse and human hepatocytes. In single-dose studies in the C57BL/6-PiZ mouse model, KRRO-111 produced up to 91% SERPINA1 editing, with M-AAT accounting for up to 88% of total circulating AAT, and both responses remaining detectable through at least Day 42 post-dose.

In repeat-dose studies, KRRO-111 produced sustained RNA editing and restoration of circulating M-AAT across multiple subcutaneous dosing regimens. In NSG-PiZ mice, SERPINA1 mRNA editing reached 96%, with M-AAT comprising 93% of total circulating AAT and total AAT concentrations reaching 172 μM (~6-fold vs. vehicle) at Day 57. In immunocompetent C57BL/6-PiZ mice, KRRO-111 reduced whole liver Z-AAT levels by 95% relative to vehicle control, as measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) at Day 57.

“People living with AATD face both lung and liver disease. Augmentation therapy addresses only part of that burden while there is no approved therapy for the liver disease,” said Ram Aiyar, PhD, MBA, Chief Executive Officer and President of Korro. “Based on the strength and consistency of these data, we believe KRRO-111 has the potential to become a transformative therapy for both the lung and liver manifestations of AATD, and we look forward to advancing it into the clinic in the first half of 2027.”

Regulatory submission for KRRO-111 is expected in the first half of 2027.

About Alpha-1 Antitrypsin Deficiency (AATD)

AATD is a genetic disorder most commonly caused by a single missense mutation (G-to-A) in the SERPINA1 gene. Affected adults experience pulmonary emphysema and/or hepatic cirrhosis, as well as end organ manifestations. Greater than 95% of severe clinical cases of AATD are homozygous for the PiZ mutation (known as the PiZZ genotype). There are an estimated 3.4 million individuals with deficiency allele combinations worldwide. The only current FDA-approved treatment for AATD is augmentation therapy, a once-weekly infusion of pooled human plasma-derived AAT protein, which remains inadequate to address the lung and liver manifestations of AATD.

About Korro

Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an REO-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions or strategies of Korro regarding the future including, without limitation, express or implied statements regarding: the best-in-class and best-in-disease potential of, and market opportunity for, KRRO-111 as a treatment for AATD, including its potential to address both the lung and liver manifestations of AATD and to become a transformative therapy, and its potential as a redosable subcutaneous therapy; the extent to which preclinical results for KRRO-111, including M-AAT restoration and reduction and clearance of Z-AAT observed in mouse models, will be predictive of results in humans; KRRO-111’s ability to achieve the functional equivalent of a DNA modification without altering the genome; the ongoing GLP toxicology evaluation of KRRO-111; the timing of a regulatory submission for KRRO-111, including the expected submission in the first half of 2027; and the advancement of KRRO-111 into clinical development and reaching and reporting clinical milestones for KRRO-111; among others. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by Korro and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including risks associated with pre-clinical studies and conducting clinical trials; risks associated with validating in clinical trials observations from pre-clinical studies, including the risk that results of pre-clinical studies, including in animal models, may not be predictive of results in humans; competition from other companies and therapies, and the absence of head-to-head comparisons supporting any best-in-class potential; risks associated with collaborating with third parties; changes in policies, staffing or priorities at the FDA or other regulatory authorities; other risks associated with obtaining regulatory approvals and protecting intellectual property; as well as risks associated with general economic conditions; and other risks and uncertainties indicated from time to time in Korro’s filings with the Securities and Exchange Commission (SEC), including under the caption “Risk Factors” in Korro’s most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K, as such may be amended or supplemented by its other filings with the SEC. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, Korro does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Korro.

Korro Bio Contact Information

Investor & Media Contact
Malini Chatterjee, PhD
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269

GREAT NECK, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) — Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) announced today that its board of directors has declared a quarterly dividend of $0.105 per share to be paid to all shareholders of record on December 31, 2026. The dividend will be paid on January 15, 2027.

Contact:
Assaf Ran, CEO
(516) 444-3400
www.linkedin.com/in/assafran
SOURCE: Manhattan Bridge Capital, Inc.

Management to Host Conference Call November 9 at 8:30 a.m. ET

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced it will host a conference call to discuss its third quarter 2026 financial results on Monday, November 9, 2026, at 8:30 a.m. ET. Participants can access the conference call via a webcast at Village Farms Third Quarter 2026 Conference Call Webcast or on the Company website at Village Farms – Events. Participants wanting to access the conference call by telephone must register in advance at Village Farms Third Quarter 2026 Conference Call Registration to receive telephone dial-in information.

The live question and answer session will be limited to analysts; however, others are invited to submit questions ahead of the conference call via email at investorrelations@villagefarms.com. Management will address questions received via email during the question and answer session as time permits.

The Company expects to report its third quarter 2026 financial results via news release on Monday, November 9, 2026, at 7:00 a.m. ET.

Conference Call Archive Access Information

For those unable to participate in the conference call at the scheduled time, it will be archived for replay beginning approximately one hour following completion of the call on Village Farms’ web site at http://villagefarms.com/investor-relations/investor-calls.

About Village Farms International

Village Farms is a global leader in cannabis, plant-based consumer packaged goods, and sustainable innovation. With a legacy built on decades of Controlled Environment Agriculture expertise and Dutch farming practices, today the Company is one of the world’s largest and most profitable cannabis operators with an asset portfolio that spans over 7 million square feet of advanced greenhouse and indoor cultivation assets.

In Canada, Village Farms operates the world’s largest EU-GMP certified cannabis facility at its production campus in Delta, British Columbia, and exports products to international medical markets. The Company is also a market share leader in dried flower formats and produces and distributes some of the country’s highest quality and best-selling strains, including its flagship Pure Sunfarms Pink Kush, one of the most widely consumed strains on the planet. Village Farms’ Canadian brand portfolio includes Pure Sunfarms, Fraser Valley Weed Co., Soar, Super Toast, Pure Laine, Tam Tams and Promenade.

In the Netherlands, the Company is one of only ten licensed operators in the country’s regulated cannabis program, and in the United States its CBDistillery brand is one of the country’s premier cannabinoid wellness platforms, and it also holds equity interests in cannabis businesses in Australia and Germany. Beyond cannabis, the Company holds an equity interest in Verdexa Holdings, a private venture pursuing strategic acquisitions to build a premier branded food platform, and its Clean Energy division transforms landfill gas into renewable natural gas and receives royalties on all revenues generated.

Contact Information

Sam Gibbons Senior Vice President, Corporate Affairs & Investor Relations Phone: (407) 495-5067 Email: sgibbons@villagefarms.com

Announcement Highlights:

            (i)      First purchase order (PO) from a strategic AI Customer marks a key commercial milestone in the Company’s MicroLED optical interconnect business.

            (ii)      PO includes a statement of work (SOW) for delivery of ultra high-performance MicroLED chips designed specifically for AI optical interconnects.

            (iii)      Palomino is focusing on MicroLED performance, reliability and manufacturing supply chain to meet the current customer’s stringent design requirements.

GOLETA, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — Palomino Laboratories, Inc. (OTCQB: PALX) (“Palomino” or the “Company”), an artificial intelligence (AI) interconnect product company, today announced it has received its first purchase order (PO) from a strategic hyperscaler customer. The PO includes a statement of work (SOW) for the delivery of high-performance gallium nitride (GaN) MicroLED chips for optical interconnect applications within AI infrastructure.

The Company believes this initial PO represents validation of its core market thesis. Specifically, MicroLED technology originally designed for the display market is not optimized for optical interconnect applications and therefore must be engineered specifically for high-speed data. Subsequently, MicroLED chip performance must be tailored to AI data center link budgets and aligned to customer system requirements.

Under the SOW, Palomino expects to improve both nanomaterial and MicroLED design to increase output power and fiber coupling efficiency performance, consistent with the Company’s technical roadmap. All other MicroLED technical parameters from Palomino’s technology platform are compliant with the customer’s target requirements.

Jeffrey B. Shealy, Co-Founder and CEO, commented: “This first commercial PO from our hyperscaler customer is a significant corporate milestone for Palomino. It confirms that leading AI infrastructure customers recognize that MicroLEDs for optical interconnects must be engineered for bandwidth, reliability and efficiency driven by the AI market.” Mr Shealy continued, “This SOW aligns directly with our AI interconnect product roadmap, and we are executing with urgency to deliver technical performance while addressing the manufacturing supply chain required for volume production.”

Dr. Steven DenBaars, Co-founder and Director of Palomino Laboratories, Inc. and pioneer of GaN MicroLED technology, added: “MicroLEDs are a powerful device platform and optical interconnect architectures impose very different performance constraints relative to those for display applications. Palomino’s work is grounded in foundational GaN MicroLED innovation and protected by our IP portfolio that includes licence rights to University of California, Santa Barbara (UCSB) patents. This PO reflects growing customer recognition that novel material science and MicroLED device design are crucial to unlock the efficiency advantages needed for next-generation AI interconnects.”

Palomino believes the receipt of this first PO is consistent with, and supports, the Company’s previously stated objective that it would secure a development contract from a strategic AI customer in Q4 FY26. The Company expects this work will further strengthen customer engagement and accelerate progress toward MicroLED-enabled optical interconnect solutions for short-reach AI systems.

About Palomino Laboratories
Palomino Laboratories is an artificial intelligence (AI) interconnect technology company headquartered in Goleta, California, developing next-generation connectivity solutions for the rapidly evolving AI infrastructure market. The Company’s product focus addresses AI interconnect solutions in the 0-to-50 meters range and includes: (i) silicon chipsets enhancing the speed of copper, (ii) silicon optical integrated circuits (IC’s) optimizing the performance of MicroVCSEL interconnects, and (iii) silicon and gallium nitride IC’s for MicroLED interconnects. Our chipsets enable high-bandwidth, low-latency, and energy-efficient data movement across AI systems. Palomino’s solutions are designed to support the growing performance demands of AI, high-performance computing (HPC), enterprise networking, hyperscale data centers and advanced robotics as increasingly intelligent systems require faster, more efficient, and more reliable data connectivity.

For more information, please visit www.palominolabs.ai.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as “expects,” “anticipates,” “intends,” “plans,” “could,” “believes,” “estimates” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the factors listed under “Risk Factors” in the Company’s filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

For further information
Palomino Laboratories Inc.
Jeffrey B. Shealy, CEO
Email: IR@palominolabs.ai

Long Island’s Original Craft Brewery Invites Beer Fans to an Afternoon of Cask Ales, Live Music and Local Food Trucks at its 22nd Annual Festival

PATCHOGUE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) — One of Long Island’s longest-running craft beer celebrations is returning to Main Street. Blue Point Brewing Co., Long Island’s original craft brewery and a subsidiary of Tilray Brands (NASDAQ: TLRY and TSX: TLRY), today announced the return of its 22nd Annual Cask Ales Festival on Saturday, November 7, 2026, from 2 to 6 p.m. at the Blue Point Brewpub, 225 West Main Street in Patchogue, New York.

The annual festival will pour samples from more than 100 casks, giving beer fans a chance to try small-batch and one-of-a-kind brews from breweries across the country. The afternoon will also feature local food trucks and live music from Blink 180 and The 90s Band.

“Cask Fest has become a true Long Island beer tradition, and we’re proud to bring it back to Patchogue for its 22nd year,” said Chris DiOrio, Senior Brand Manager, Blue Point Brewing. “It’s a chance for the community to come together, discover rare cask ales and celebrate the creativity that has always been at the heart of Blue Point.”

General admission tickets are $40 and include festival admission, a 5-ounce Cask Fest tasting glass and beer samples from more than 100 casks. Tickets are available here.

After the festival, the party will move indoors to the tasting room from 6 to 10 p.m., where The 90s Band will keep the music going into the evening.

The event will be held rain or shine and is open only to guests ages 21 and older. For full event details, visit Blue Point Brewing’s Cask Fest 2026 event page.

About Blue Point Brewing

Blue Point Brewing Company was founded in 1998 in Patchogue, New York and is Long Island’s OG craft brewery. Twenty-seven years later, with a widely appealing portfolio of beer and beyond beer brands, Blue Point has grown to be one of the largest breweries in New York, with a footprint up and down the entire East Coast. Blue Point’s flagship beer, Toasted Lager, has won several awards including a gold medal at the World Beer Cup.

For more information about Blue Point Brewing, please visit www.bluepointbrewing.com and follow us on Instagram @BluePointBrewing.

About Tilray Brands

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information, please contact

Media: news@tilray.com
Investors: investors@tilray.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f0c3ed03-4d7e-437c-895b-e249030f3a0e

Net Sales Increased 34%, Driven by Vita Coco Coconut Water Growth of 15%; Organic Net Sales Growth¹ of 18%

Net Income Increased $11 million to $35 million and Non-GAAP Adjusted EBITDA² Increased $21 million to $53 million

Raises Fiscal Year 2026 Guidance for Net Sales to Between $810 Million and $820 Million and Non-GAAP Adjusted EBITDA² to between $170 million and $175 million

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the third quarter ended September 30, 2026.

Third Quarter and Year-to-Date 2026 Highlights Compared to Prior Year Period

• Net sales were $244 million, an increase of $62 million, or 34%, in the third quarter, and $640 million year-to-date, an increase of $158 million, or 33%.
• Organic net sales growth¹ was 18% in the third quarter and 27% year-to-date.
• Vita Coco Coconut Water net sales grew 15% in the third quarter and 24% year-to-date.
• Private Label net sales grew 152% in the third quarter and 85% year-to-date, with the third quarter benefiting from the contribution of Copra, a leading producer of super premium Thai Nam Hom coconut water that was acquired in July 2026.
• Gross profit was $93 million in the third quarter, an increase of $24 million, and $270 million year-to-date, an increase of $92 million.

• Gross margin was 38% of net sales in the third quarter consistent with prior year, and was 42% of net sales year-to-date compared to 37%, with tariff refunds delivering a 240 basis point benefit to gross margin year-to-date.
• Net income was $35 million in the third quarter, compared to $24 million, an increase of $11 million, and $115 million year-to-date, compared to $66 million, an increase of $49 million.

• Net income per diluted share was $0.58 in the third quarter, compared to $0.40, and $1.89 per diluted share year-to-date, compared to $1.10.
• Non-GAAP Adjusted EBITDA² was $53 million in the third quarter, compared to $32 million, an increase of $21 million. Non-GAAP Adjusted EBITDA² was $159 million year-to-date, compared to $84 million, an increase of $75 million.

Michael Kirban, the Company’s Co-Founder and Executive Chairman, stated, “The growth of the coconut water category maintained through the fall, and remains one of the fastest growing beverage categories in our major markets. I am particularly pleased by the strong growth in Europe as we develop the category in key markets, and the continued growth in America, driven by increases in both household penetration and in average consumption per household. This quarter, we were pleased to welcome the Copra team to our family and to start executing our joint plans, which we believe will allow us to compete successfully in the super premium segment. With the investments we are making in our supply chain, and our strong brand performance, I am confident in our plans to maintain our growth into 2027, and our category leadership well into the future.”

Martin Roper, the Company’s Chief Executive Officer, said, “Our strong third quarter net sales growth was driven by robust branded retail growth in all our major markets, and by strong growth in private label shipments, reflecting healthy category growth and the addition of Copra’s super premium products. Excluding the impact of Copra, the underlying 18% organic net sales growth of our business remained very strong, exceeding our expectations. Consumer demand is very healthy, and we are therefore raising our full year Net Sales and Adjusted EBITDA guidance.”

Third Quarter 2026 Consolidated Results

Net sales increased $62 million, or 34%, to $244 million for the third quarter ended September 30, 2026, compared to $182 million in the prior year period. The increase in net sales was driven by case equivalent (“CE”) volume gains of 16% for Vita Coco Coconut Water and 77% for Private Label. Organic net sales growth¹, which is net sales growth excluding the impact of Copra, was 18% for the quarter. Copra net sales primarily impacted Private Label, with Copra branded coconut water and commodity net sales recognized in Other.

Gross profit increased to $93 million, from $69 million in the prior year period driven by higher sales volume, the addition of Copra, and minimal tariffs compared to the prior year period, partially offset by higher domestic logistics costs. Gross margin was 38%, in line with the prior year period, benefitting from minimal tariffs compared to the prior year period, offset by higher domestic logistics costs, and the dilutive impact of Copra.

Selling, general and administrative (“SG&A”) expenses were $47 million, compared to $41 million in the prior year period. The increase was primarily driven by costs related to the acquisition of Copra, amortization expense associated with intangible assets acquired in the Copra acquisition, higher people-related costs reflecting increased headcount and stock-based compensation, as well as higher sales related expenses.

Net income was $35 million, or $0.58 per diluted share, compared to net income of $24 million, or $0.40 per diluted share, in the prior year period. Net income benefited from higher gross profit, partially offset by higher SG&A spending and increased income tax expense.

Non-GAAP Adjusted EBITDA² was $53 million, compared to $32 million in the prior year due to the increased gross profit partially offset by higher SG&A expenses.

Balance Sheet

As of September 30, 2026, the Company’s financial position remained strong with no debt and $152 million in cash and cash equivalents. Cash decreased $45 million from the beginning of the year, and $127 million from end of the second quarter due to net cash used for the acquisition of Copra of $139 million. Our inventory was $111 million, flat to December 31, 2025, with the inclusion of Copra inventory offsetting the inventory draw down from strong year-to-date shipments. Accounts receivable increased to $129 million from $82 million as of prior year end due to strong quarterly sales and the inclusion of Copra.

As of September 30, 2026, the Company had repurchased approximately $86 million of its common stock under its share repurchase program and had $19 million remaining under the existing authorization. During the nine months ended September 30, 2026, the Company repurchased $62 million of its common stock. As of October 22, 2026, the Company has repurchased $94 million of its common stock, and had $11 million remaining of the $105 million authorized amount under the repurchase program.

Fiscal Year 2026 Full Year Outlook³

The Company is increasing its full year 2026 guidance, as follows:

• Net sales expected to be between $810 million and $820 million, driven by low 20s percent growth of Vita Coco Coconut Water, strong Private Label trends and the addition of Copra. (Prior guidance was between $790 million and $805 million, which included the benefit of Copra).
• Gross margin expected to be approximately 40% with benefit relative to prior year from lower tariffs, tariff refunds, and higher pricing partially offset by increased ocean freight, product and other transportation costs, alongside adverse product mix, primarily due to the impact of Copra’s private label business and strong private label trends. (No change from prior guidance). Fourth quarter gross margin expected to be approximately 33% due to increases in cost of goods and no offsetting price actions expected until early 2027.
• Expect to deliver SG&A leverage of approximately 1.5 percentage points of net sales vs. 2025. (Prior guidance was one percentage point).
• Adjusted EBITDA² expected to be in the range of $170 million to $175 million. (Prior guidance was between $154 million and $161 million).

Uncertainty and instability in the current operating environment, geopolitical landscape, and global economies, including the military conflict in Iran and related impacts, changes in tariff rates, natural disasters, associated potential competitive pricing actions, and our own price elasticity could affect this outlook and our future results.

Footnotes

(1)	Organic net sales growth is a supplemental measure of net sales performance that excludes the impact of net sales attributable to the Copra acquisition as set forth in the U.S. GAAP to non-GAAP reconciliation table below.
(2)	Adjusted EBITDA represents earnings before interest, taxes, depreciation, and amortization as adjusted for certain items as set forth in the reconciliation table of U.S. GAAP to non-GAAP information and is a measure calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Non-GAAP Financial Measures herein for further discussion and reconciliation of this measure to GAAP measures.
(3)	GAAP Net income 2026 outlook is not provided due to the inherent difficulty in quantifying certain amounts due to a variety of factors including the unpredictability in the movement in foreign currency rates, as well as future charges or reversals outside of the normal course of business.

Conference Call and Webcast Details

To participate in the live earnings call and question and answer session, please register at https://register-conf.media-server.com/register/BIb7dfca7ed24e41c7a1cd98a3f2cfb4e0 and dial-in information will be provided directly to you. The live audio webcast will be accessible in the “Events” section of the Company’s Investor Relations website at https://investors.thevitacococompany.com. An archived replay of the webcast will be available shortly after the live event has concluded.

About The Vita Coco Company

The Vita Coco Company is a family of brands on a mission to reimagine what’s possible when brands deliver healthy, nutritious, and great tasting products that are better for consumers and better for the world. This includes its flagship coconut water brand Vita Coco, and Copra, a super-premium brand that specializes in Thai Nam Hom coconut water. The Company was co-founded in 2004 by Michael Kirban and Ira Liran and is a public benefit corporation and Certified B Corporation. Vita Coco, the principal brand within the Company’s portfolio, is the leading coconut water brand in the U.S. With electrolytes and nutrients, coconut water has become a top beverage choice among consumers after a workout, in smoothies, as a cocktail mixer, after a night out and more.

Contacts

Investor Relations:
ICR, Inc.
investors@thevitacococompany.com

Non-GAAP Financial Measures

In addition to disclosing results determined in accordance with U.S. GAAP, the Company also discloses certain non-GAAP results of operations, including, but not limited to, Adjusted EBITDA, and organic net sales growth, which include certain adjustments or exclude certain charges and gains that are described in the reconciliation table of U.S. GAAP to non-GAAP information provided at the end of this release. These non-GAAP measures are a key metric used by management and our board of directors to assess our financial performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance and because we believe it is useful for investors to see the measures that management uses to evaluate the Company. In addition, we believe the presentation of these measures is useful to investors for period-to-period comparisons of results as the items described below in the reconciliation tables do not reflect ongoing operating performance.

These measures are not in accordance with, or an alternative to, U.S. GAAP, and may be different from non-GAAP measures used by other companies. In addition, other companies, including companies in our industry, may calculate such measures differently, which reduces their usefulness as a comparative measure. Investors should not rely on any single financial measure when evaluating our business. This information should be considered as supplemental in nature and is not meant as a substitute for our operating results in accordance with U.S. GAAP. We recommend investors review the U.S. GAAP financial measures included in this earnings release. When viewed in conjunction with our U.S. GAAP results and the accompanying reconciliations, we believe these non-GAAP measures provide greater transparency and a more complete understanding of factors affecting our business than U.S. GAAP measures alone.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our future financial and operating performance, including our GAAP and non-GAAP guidance, our strategy, projected costs, tariffs, prospects, expectations, plans, objectives of management, supply chain predictions, customer and supplier relationships, expected impact of acquisitions, and expected net sales and category share growth.

The forward-looking statements in this release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond the Company’s control. These factors include, but are not limited to, those discussed under the caption “Risk Factors” in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and our other filings with the U.S. Securities and Exchange Commission (“SEC”) as such factors may be updated from time to time and which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of our website at https://investors.thevitacococompany.com. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

Website Disclosure

We intend to use our websites, vitacoco.com and investors.thevitacococompany.com, as a means for disclosing material non-public information and for complying with the SEC’s Regulation FD and other disclosure obligations.

THE VITA COCO COMPANY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share data)
	September 30, 2026				December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$	151,995			$	196,873
Accounts receivable, net of allowance of $3,282 at September 30, 2026, and $2,660 at December 31, 2025		128,724				81,514
Inventory		111,296				111,468
Supplier advances, current		339				693
Derivative assets		1,794				732
Prepaid expenses and other current assets		39,536				30,160
Total current assets		433,684				421,440
Property and equipment, net		24,441				9,298
Goodwill		110,175				7,791
Intangible assets, net		107,116				—
Supplier advances, long-term		1,593				1,860
Deferred tax assets, net		6,627				6,623
Right-of-use assets, net		10,337				11,592
Other assets		2,169				2,714
Total assets	$	696,142			$	461,318
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	46,389			$	25,464
Accrued expenses and other current liabilities		126,632				89,461
Derivative liabilities		2,059				1,507
Total current liabilities		175,080				116,432
Deferred tax liability		24,875				160
Operating lease liability, long-term		12,119				13,087
Seller’s earn-out		55,100				—
Other long-term liabilities		240				97
Total liabilities	$	267,414			$	129,776
Stockholders’ equity:
Common stock, $0.01 par value; 500,000,000 shares authorized; 65,396,253 and 64,186,549 shares issued at September 30, 2026 and December 31, 2025, respectively; 57,202,356 and 57,082,173 shares outstanding at September 30, 2026 and December 31, 2025, respectively.		654				642
Additional paid-in capital		231,578				185,400
Retained earnings		342,956				228,014
Accumulated other comprehensive gain (loss)		(1,050	)			486
Treasury stock, 8,193,897 shares at cost as of September 30, 2026, and 7,104,376 as of December 31, 2025.		(145,410	)			(83,000	)
Total stockholders’ equity		428,728				331,542
Total liabilities and stockholders’ equity	$	696,142			$	461,318

THE VITA COCO COMPANY, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except for share and per share data)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Net sales	$	243,825			$	182,313			$	639,744			$	481,993
Cost of goods sold		151,148				113,645				369,942				303,975
Gross profit		92,677				68,668				269,802				178,018
Operating expenses
Selling, general and administrative		47,226				40,745				127,629				105,680
Income from operations		45,451				27,923				142,173				72,338
Other income (expense)
Unrealized (loss) gain on derivative instruments		(2,083	)			2,391				511				6,275
Foreign currency loss		(887	)			(1,411	)			(2,432	)			(349	)
Interest income, net		1,231				1,776				5,252				4,794
Other (expense) income, net		(84	)			—				(77	)			155
Total other (expense) income		(1,823	)			2,756				3,254				10,875
Income before income taxes		43,628				30,679				145,427				83,213
Income tax expense		8,611				6,676				30,485				17,420
Net income	$	35,017			$	24,003			$	114,942			$	65,793
Net income attributable to The Vita Coco Company, Inc. per common share
Basic	$	0.61			$	0.42			$	2.01			$	1.16
Diluted	$	0.58			$	0.40			$	1.89			$	1.10
Weighted-average number of common shares outstanding
Basic		57,453,252				56,850,812				57,274,270				56,879,627
Diluted		60,831,632				59,878,602				60,786,462				59,832,067

THE VITA COCO COMPANY, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands)
	Nine Months Ended September 30,
	2026				2025
Cash flows from operating activities:
Net income	$	114,942			$	65,793
Adjustments required to reconcile net income to cash flows from operating activities:
Depreciation and amortization		2,458				636
Amortization of debt issuance cost		14				11
Increase of provision for credit losses		187				1,300
Unrealized (gain) on derivative instruments		(511	)			(6,275	)
Stock-based compensation		11,338				8,123
Impairment loss on Runa assets		—				185
Noncash lease expense		1,242				1,052
Changes in operating assets and liabilities:
Accounts receivable		(42,801	)			(39,706	)
Inventory		33,259				(302	)
Prepaid expenses, net supplier advances, and other assets		(7,236	)			345
Accounts payable, accrued expenses, and other liabilities		39,050				19,907
Net cash provided by operating activities		151,942				51,069
Cash flows from investing activities:
Cash paid for property and equipment		(803	)			(4,921	)
Acquisition of Copra Inc., net of $8,340 cash acquired		(139,253	)			—
Net cash used in investing activities		(140,056	)			(4,921	)
Cash flows from financing activities:
Proceeds from exercise of stock awards		6,131				2,281
Cash paid on notes payable		(3	)			(8	)
Cash paid to acquire treasury stock		(62,410	)			(10,204	)
Net cash used in financing activities		(56,282	)			(7,931	)
Effects of exchange rate changes on cash and cash equivalents		(475	)			833
Net (decrease) increase in cash and cash equivalents		(44,871	)			39,050
Cash, cash equivalents and restricted cash at beginning of the period (1)		198,154				165,933
Cash, cash equivalents and restricted cash at end of the period (1)	$	153,283				204,983

¹ Includes $1,281 and $1,264 of restricted cash as of December 31, 2025 and 2024, respectively. Includes $1,288 and $1,278 of restricted cash as of September 30, 2026 and 2025, respectively, reported in other current assets on the condensed consolidated balance sheet.

During the nine months ended September 30, 2026, the Company issued common stock with a fair value of $35,000 and recognized contingent consideration with a fair value of $55,100 in connection with the acquisition of Copra. These transactions are reflected as noncash investing and financing activities.

RECONCILIATION FROM GAAP NET INCOME TO NON-GAAP ADJUSTED EBITDA
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
	(in thousands)								(in thousands)
Net income		35,017				24,003			$	114,942			$	65,793
Depreciation and amortization		1,493				228				2,458				636
Interest income, net		(1,231	)			(1,776	)			(5,252	)			(4,794	)
Income tax expense		8,611				6,676				30,485				17,420
EBITDA	$	43,890			$	29,131			$	142,633			$	79,055
Stock-based compensation (a)		3,122				2,975				11,338				8,123
Unrealized loss (gain) on derivative instruments (b)		2,083				(2,391	)			(511	)			(6,275	)
Foreign currency loss (b)		887				1,411				2,432				349
Acquisition-related costs (c)		3,174				—				3,174				—
Other adjustments (d)		—				1,264				—				2,886
Adjusted EBITDA	$	53,156			$	32,390			$	159,066			$	84,138

(a)	Non-cash charges related to stock-based compensation, which vary from period to period depending on volume and vesting timing of awards and forfeitures. We adjusted for these charges to facilitate comparison from period to period.
(b)	Unrealized gains or losses on derivative instruments and foreign currency gains or losses are not considered in our evaluation of our ongoing performance.
(c)	Acquisition-related costs represent transaction, advisory, legal, accounting, valuation, and other professional fees incurred in connection with the acquisition of Copra.
(d)	The three and nine months ended September 30, 2025 included $0.6 million and $1.8 million, respectively, related to a one-time incentive program established in 2023 and measured based on full-year 2025 performance, and $0.4 million and $1.1 million, respectively, of overlapping rent expense associated with our new New York City office, and $0.2 million of impairment loss related to the sale of Runa. The three months ended September 30, 2025 also includes $0.1 million of provision for credit losses related to the partially recovered prepaid inventory from a supplier recorded in the first half of 2025 (refer to the Form 10-K and the Form 10-Q for the quarterly period ended June 30, 2025 for further details). The nine month period was partially offset by $0.1 million of partial recoveries of prepaid inventory from a supplier (refer to the Form 10-K for further details) and a $0.2 million gain from a sale of intellectual property.

RECONCILIATION FROM GAAP NET SALES GROWTH TO NON-GAAP ORGANIC NET SALES GROWTH
	Three Months Ended September 30, 2026			Nine Months Ended September 30, 2026
Net sales growth	33.7	%		32.7	%
Impact of Copra acquisition	16.0	%		6.0	%
Organic net sales growth	17.8	%		26.7	%

SUPPLEMENTAL INFORMATION

	NET SALES
	Three Months Ended September 30,						Nine Months Ended September 30,
(in thousands)	2026			2025			2026			2025
Americas segment
Vita Coco Coconut Water	$	143,276		$	132,438		$	399,231		$	339,006
Private Label		46,495			14,360			97,795			50,242
Other		8,786			4,926			22,162			17,037
Subtotal	$	198,557		$	151,724		$	519,188		$	406,285
International segment
Vita Coco Coconut Water	$	34,363		$	21,939		$	88,645		$	54,998
Private Label		10,297			8,137			30,462			19,118
Other		608			513			1,449			1,592
Subtotal	$	45,268		$	30,589		$	120,556		$	75,708
Total net sales	$	243,825		$	182,313		$	639,744		$	481,993

	COST OF GOODS SOLD & GROSS PROFIT
	Three Months Ended September 30,								Nine Months Ended September 30,
(in thousands)	2026				2025				2026				2025
Cost of goods sold
Americas segment	$	122,824			$	93,859			$	293,240			$	255,062
International segment		28,324				19,786				76,702				48,913
Total cost of goods sold	$	151,148			$	113,645			$	369,942			$	303,975
Gross profit
Americas segment	$	75,732			$	57,866			$	225,948			$	151,224
International segment		16,945				10,802				43,854				26,794
Total gross profit	$	92,677			$	68,668			$	269,802			$	178,018
Gross margin
Americas segment		38.1	%			38.1	%			43.5	%			37.2	%
International segment		37.4	%			35.3	%			36.4	%			35.4	%
Consolidated		38.0	%			37.7	%			42.2	%			36.9	%

	VOLUME (CE)
	Percentage Change – Three Months Ended September 30, 2026 vs. 2025
	Americas segment			International segment			Total
Vita Coco Coconut Water	8.5	%		50.5	%		15.8	%
Private Label	109.9	%		23.1	%		76.7	%
Other	34.9	%		108.7	%		35.8	%
Subtotal	22.5	%		42.1	%		26.5	%
	Percentage Change – Nine Months Ended September 30, 2026 vs. 2025
	Americas segment			International segment			Total
Vita Coco Coconut Water	13.2	%		52.5	%		19.7	%
Private Label	63.4	%		48.8	%		58.9	%
Other	16.6	%		(14.2	)%		15.8	%
Subtotal	21.2	%		51.0	%		26.8	%

Note: A CE is a standard volume measure used by management which is defined as a case of 12 bottles of 330ml liquid beverages or the same liter volume of oil. We may have immaterial sales of raw materials at times that are treated as zero CEs for the purposes of these calculations.

• Introducing the industry’s first Industrial AI Agents at the Edge, providing a practical pathway to Physical AI
• Built on HPE Private Cloud AI, autonomous AI agents operate directly within industrial environments, continuously monitoring, reasoning, and optimizing operations in real time
• Addresses three key barriers to industrial AI adoption at scale: data sovereignty, cybersecurity and AI consumption costs

BERLIN, Oct. 22, 2026 (GLOBE NEWSWIRE) — Schneider Electric, a global energy technology leader, today announced a strategic collaboration with NVIDIA and HPE to accelerate the adoption of Physical AI across process and heavy industries.

While much of today’s Physical AI conversation is focused on robotics, humanoids and autonomous machines, process industries face a distinctly different challenge. Operators must manage complex, continuous operations where reliability, safety, cybersecurity and energy efficiency are critical to performance. Yet until now, there has been no clear blueprint for how Physical AI can be practically applied across these complex environments.

Schneider Electric, NVIDIA & HPE share a vision to bring AI closer to industrial operations, embedding intelligence directly within the environments where decisions are made and value is created. As an initial demonstration of this vision, the companies are today introducing Industrial AI Agents at the Edge.

The solution combines HPE Private Cloud AI, co-engineered with NVIDIA within the HPE AI Factory with NVIDIA portfolio Schneider Electric’s deep operational technology expertise to enable organizations to securely deploy and scale AI applications at the industrial edge, bringing real-time intelligence closer to critical operations while maintaining control over sensitive data, security and costs.

Many industrial organizations continue to face challenges when scaling AI across operational environments. Requirements around data governance, cybersecurity, operational performance and AI deployment can create barriers to broader adoption. By operating at the edge, the solution helps address three challenges that continue to limit industrial AI at scale:

• Data sovereignty. Critical operational data is often too valuable, sensitive or regulated to move beyond operational boundaries. HPE Private Cloud AI provides the secure foundation for Industrial AI Agents at the Edge, enabling organizations to deploy AI close to operations while maintaining control, security, and compliance.
• Cybersecurity. Increased connectivity can introduce additional risk across industrial and critical infrastructure environments. HPE Private Cloud AI reduces the attack surface by keeping and processing the data close to its source.
• AI consumption costs. As AI usage grows, cloud-based inference, data transfer and token-related costs can increase, creating challenges for organizations looking to scale AI across sites, assets and operations. Deploying AI at the edge with HPE Private Cloud AI can help reduce some of these costs while providing greater control over where and how AI workloads are executed.

Through Schneider Electric’s EcoStruxure Industrial Insights apps customers can deploy, manage and govern multiple Industrial AI Agents through a single environment, simplifying lifecycle management, security oversight and maintaining full control of critical operations and infrastructure.

The first Industrial AI Agents focus on operational technology monitoring, cybersecurity and energy optimization. Their practical application can already be seen in industrial environments with companies such as CMPC Chile.

Operational Technology Monitoring System in Production: CMPC

The foundation for this next step is already proven at CMPC Chile, part of Empresas CMPC S.A., one of Latin America’s largest pulp, paper and packaging producers. For the past three years, CMPC Chile has used Schneider Electric’s OTMS in production to monitor the health and availability of control systems across its continuous pulp and paper operations.

OTMS provides CMPC’s teams with a unified view of control systems, servers, workstations and switches, helping specialists identify emerging issues earlier, diagnose problems faster and establish clearer maintenance priorities. This proven deployment demonstrates the value of OTMS as a control-system monitoring solution and provides a strong operational foundation for the future introduction of Industrial AI Agents, with the potential to accelerate investigation and decision-making while keeping people in control of critical action.

The first three Industrial AI Agents at the edge

• OT Monitoring Agents: Combines real-time operational data, equipment configurations, process topology, alarms, maintenance history and engineering context to understand the physical state of industrial operations. The agents identify emerging issues, reasons about likely operational impacts, recommends or initiates corrective actions, and verifies that the intervention delivers the expected physical outcome.
• Cybersecurity Agents: Correlates network activity, control system behaviour, asset configurations, operational events and process context to detect abnormal conditions. The agents assess potential impacts on industrial operations, recommends or executes response measures, and validates that systems have returned to a secure and stable state.
• Energy Optimization Agents: Integrates process data, energy consumption patterns, equipment performance, operating conditions and production requirements to understand how energy is used across industrial operations. The agents identify optimization opportunities, recommends or implements adjustments, and verifies the resulting impact on energy efficiency, operational performance and sustainability outcomes.

“The next generation of industrial innovation will be driven by intelligence embedded directly into industrial operations,” said Gwenaelle Huet, Executive Vice President, Industrial Automation, Schneider Electric. “While much of today’s focus is on autonomous machines, we see a significant opportunity to apply Physical AI to the industrial systems that power the world’s critical industries. Together with NVIDIA and HPE, we are bringing together expertise in automation, AI and edge computing to help customers transform operational data into action, improving resilience, efficiency, cybersecurity and sustainability while laying the foundation for more autonomous industrial operations.”

“Industrial operations generate vast amounts of data, but turning that data into action remains one of industry’s biggest challenges. By combining NVIDIA Nemotron™ open AI models and HPE Private Cloud AI, a turnkey AI factory solution, with Schneider Electric’s industrial expertise and OTMS platform, Industrial AI Agents can monitor, reason and optimize operations in real time, accelerating the path to Physical AI for process industries,” commented Sri Kodali, Global Head of Developer Relations – Energy and Utilities at NVIDIA.

“Industrial organizations see real opportunities to use AI, and they want to be sure their sensitive data and critical systems will remain protected. Through our collaboration with NVIDIA and Schneider Electric, we’re helping customers use HPE Private Cloud AI to bring AI closer to where their data is generated and decisions are made. This gives customers a way to expand AI use across their facilities while maintaining the security, privacy and control their businesses require,” said Alexia Clements, SVP, Hybrid Cloud Solution Sales at HPE.

“For the past three years, OTMS has helped us improve visibility into the health and availability of our control systems. In continuous industrial operations, identifying issues early is critical to protecting production and avoiding costly disruption. Looking ahead, we see significant potential for AI Agents to build on this proven foundation, helping our specialists investigate issues faster and move more effectively from insight to action, while keeping people in control of critical decisions,” said Matías Jory, Digital & Process Manager, Industrial Operations Vice-Presidency, CMP.

Together, Schneider Electric, NVIDIA and HPE are creating the foundation for the next generation of industrial operations, where intelligent systems can continuously monitor, reason and optimize performance. Over time, these capabilities will help automate the automation, enabling safer, more efficient and increasingly autonomous operations across process industries.

Press contact: mediarelations@se.com

About Schneider Electric

Schneider Electric is a global energy technology leader, driving efficiency and sustainability by electrifying, automating, and digitalizing industries, businesses, and homes. Its technologies enable buildings, data centers, factories, infrastructure, and grids to operate as open, interconnected ecosystems, enhancing performance, resilience, and sustainability. The portfolio includes intelligent devices, software-defined architectures, AI-powered systems, digital services, and expert advisory. With 160,000 employees and 1 million partners in over 100 countries, Schneider Electric is consistently ranked among the world’s most sustainable companies. 

www.se.com

Learn more about Advancing Energy Tech on Schneider Electric Insights.

BRAMPTON, Ontario, Oct. 22, 2026 (GLOBE NEWSWIRE) — Loblaw Companies Limited (TSX: L) announced today that it will release its 2026 third quarter results on November 19, 2026, at approximately 6:30 a.m. (ET). The release will be followed by a conference call at 10:00 a.m. (ET), as well as an audio webcast.

To access via audio webcast please go to the “Investor” section of loblaw.ca and note that pre-registration will be available. Alternatively, please dial (647) 932-3411 or Toll-Free (800) 715-9871. Following the live event, the webcast will be archived and available to replay for 12 months.

About Loblaw Companies Limited

Loblaw is Canada’s food and pharmacy leader, and the nation’s largest retailer. Loblaw provides Canadians with grocery, pharmacy, health and beauty, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 corporate franchised and Associate-owned locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada’s largest private sector employers.

Loblaw’s purpose – Live Life Well® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company’s stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart® and Pharmaprix® locations and in close to 500 grocery stores; PC Financial® services; Joe Fresh® fashion and family apparel; and four of Canada’s top-consumer brands in Life Brand®, Farmer’s Market^TM, no name® and President’s Choice®.

For more information, visit Loblaw’s website at www.loblaw.ca and Loblaw’s issuer profile at www.sedarplus.ca.

Media Enquiries, contact:

Scott Bonikowsky
Loblaw Companies Limited, Senior-Vice President Corporate Affairs and Communications
pr@loblaw.ca

Investors Enquiries, contact:

Roy MacDonald
Loblaw Companies Limited, Vice President Investor Relations
investor@loblaw.ca

BETHESDA, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) — Liquidity Services (NASDAQ:LQDT), the leading global provider of e-commerce marketplaces and software solutions powering the circular economy, today announced that it expects to report its fourth quarter and fiscal year 2026 results prior to market open on Thursday, November 19, 2026. Bill Angrick, Chairman and CEO, and Jorge Celaya, EVP and CFO, will then host a conference call to review the results at 10:30 AM Eastern Time.

To participate in the conference call, please register here to receive the dial-in number and unique conference pin. A listen-only live webcast of the conference call will also be provided on the Company’s investor relations site.

An archive of the webcast will be available on the Company’s website until November 19, 2027. To listen to the replay, visit the Liquidity Services investor relations site. The replay will be available starting at 1:30 PM Eastern Time on the day of the call.

About Liquidity Services
Liquidity Services (NASDAQ: LQDT) operates the world’s largest B2B e-commerce marketplace platform for surplus assets with over $15 billion in completed transactions to more than six million qualified buyers and 15,000 corporate and government sellers worldwide. The company supports its clients’ sustainability efforts by helping them extend the life of assets, prevent unnecessary waste and carbon emissions, and reduce the number of products headed to landfills.

Contact:
Liquidity Services
Investor Relations
InvestorRelations@LiquidityServices.com

COLUMBUS, Ohio, Oct. 22, 2026 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company’s Net principal loss rate and Delinquency rate for the periods indicated:

	For the month ended September 30, 2026				For the three months ended September 30, 2026
	(dollars in millions)
End-of-period credit card and other loans	$	18,850			$	18,850
Average credit card and other loans	$	18,740			$	18,591
Year-over-year change in average credit card and other loans		6.4	%			5.7	%
Net principal losses	$	92			$	300
Net principal loss rate		5.99	%			6.40	%

	As of September 30, 2026				As of September 30, 2025
	(dollars in millions)
30 days + delinquencies – principal	$	923			$	963
Period ended credit card and other loans – principal	$	16,584			$	15,928
Delinquency rate		5.57	%			6.04	%

About Bread Financial^®
Bread Financial^®(NYSE: BFH) is a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions to millions of U.S. consumers. Our payment solutions deliver growth for some of the most recognized brands in travel and entertainment, specialty apparel, health and beauty, jewelry, sporting goods, technology and electronics, as well as home and furniture through our co-brand and private label credit cards and pay-over-time products providing choice and value to our shared customers. Additionally, we offer Bread Financial general purpose credit cards and saving products that empower our customers and their passions for a better life.​

Bread Financial proudly marks 30 years of success in 2026. To learn more about our global associates, our performance and our sustainability progress, visit breadfinancial.com or follow us on Instagram and LinkedIn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements give our expectations or forecasts of future events and can generally be identified by the use of words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “project,” “plan,” “likely,” “may,” “should” or other words or phrases of similar import. Similarly, statements that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding, and the guidance we give with respect to, our anticipated operating or financial results, future financial performance and outlook, future dividend declarations, and future economic conditions.

We believe that our expectations are based on reasonable assumptions. Forward-looking statements, however, are subject to a number of risks and uncertainties that are difficult to predict and, in many cases, beyond our control. Accordingly, our actual results could differ materially from the projections, anticipated results or other expectations expressed in this release, and no assurances can be given that our expectations will prove to have been correct. Factors that could cause the outcomes to differ materially include, but are not limited to, the following: macroeconomic conditions, including inflation, interest rates, labor market conditions, financial and capital market conditions, recessionary pressures or concerns over a prolonged economic slowdown, and the related impact on consumer spending behavior, payments, debt levels, savings rates and other behaviors; domestic and international political events and conditions, including significant shifts in trade policy, such as changes to, or the imposition of, tariffs and/or trade barriers and consequently any economic impacts, volatility, uncertainty and geopolitical instability resulting therefrom, as well as ongoing wars and military conflicts, and international tensions or hostilities; local or global public health issues, climate-related events, impacts to the power grid, and natural disasters; future credit performance, including the level of future delinquency and charge-off rates; loss of, or reduction in demand for services and/or products from, significant brand partners or customers in the highly competitive markets in which we operate, including competition from new and non-traditional competitors, such as financial technology companies, and with respect to new products, services and technologies, such as the emergence or increase in popularity of agentic commerce, digital payment platforms and currencies and other alternative payment and deposit solutions; the concentration of our business in U.S. consumer credit; inaccuracies in the models and estimates on which we rely, including our credit risk management models and the amount of our Allowance for credit losses; the inability to realize the intended benefits of acquisitions, dispositions and other strategic initiatives; our level of indebtedness and ability to access financial or capital markets; pending and future federal and state legislation, executive action, regulation, supervisory guidance, and regulatory and legal actions, including, but not limited to, those related to financial regulatory reform and consumer financial services practices, as well as any such actions that would place limits on credit card interest rates or late fees, interchange fees or other charges; failures or breaches in our operational or security systems, including as a result of cyberattacks, unanticipated impacts from technology modernization projects or otherwise; and any liability or other adverse impacts arising out of or related to the spinoff of our former LoyaltyOne segment or the bankruptcy filings of Loyalty Ventures Inc. (LVI) and certain of its subsidiaries, including the pending litigation against us in connection with the spinoff. The foregoing factors, along with other risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements, are described in greater detail under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the most recently ended fiscal year, which may be updated in Item 1A of, or elsewhere in, our Quarterly Reports on Form 10-Q filed for periods subsequent to such Form 10-K. Our forward-looking statements speak only as of the date made, and we undertake no obligation, other than as required by applicable law, to update or revise any forward-looking statements, whether as a result of new information, subsequent events, anticipated or unanticipated circumstances or otherwise.

Contacts   
Brian Vereb — Investor Relations   
Brian.Vereb@breadfinancial.com   
   
Susan Haugen — Investor Relations   
Susan.Haugen@breadfinancial.com   
   
Rachel Stultz — Media   
Rachel.Stultz@breadfinancial.com